Production (Stage)
Protagenic Therapeutics, Inc.
PTIX
$3.62
$0.1353.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 87.35% | 45.68% | -13.18% | -18.44% | -35.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.09% | 25.94% | 32.73% | 74.70% | 86.95% |
| Operating Income | 2.09% | -25.94% | -32.73% | -74.70% | -86.95% |
| Income Before Tax | 12.75% | -10.49% | -43.87% | -85.38% | -106.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.75% | -10.49% | -43.87% | -85.38% | -106.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.75% | -10.49% | -43.87% | -85.38% | -106.31% |
| EBIT | 2.09% | -25.94% | -32.73% | -74.70% | -86.95% |
| EBITDA | 2.28% | -25.60% | -31.16% | -136.20% | -293.22% |
| EPS Basic | 30.72% | 0.59% | -40.35% | -82.04% | -103.59% |
| Normalized Basic EPS | 20.67% | -16.08% | -33.44% | -76.25% | -85.30% |
| EPS Diluted | 30.75% | 0.97% | -39.67% | -81.04% | -102.58% |
| Normalized Diluted EPS | 20.67% | -16.08% | -33.44% | -76.25% | -85.30% |
| Average Basic Shares Outstanding | 28.56% | 12.80% | 2.89% | 1.81% | 1.22% |
| Average Diluted Shares Outstanding | 28.56% | 12.80% | 2.89% | 1.81% | 1.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |